BIOSECURE Nudges Celltrion’s Jump Into CDMO Business

New Drug Development, Other Plans

 
• By Jung Won Shin

Celltrion Group chairman outlines new plans for the Korean biosimilars giant to move into the CDMO sector and updates on new drug development activities.

Celltrion Group Chairman Jungjin Seo
CDMO Subsidiary May Begin To Generate Sales From 2028

More from Strategy

More from Generics Bulletin